替比夫定治疗慢性乙型肝炎的研究进展

王海燕; 王煜; 彭晓明; 刘娅

替比夫定治疗慢性乙型肝炎的研究进展

1. 宁夏医科大学
2. 宁夏医科大学总医院感染疾病科

基金项目:

宁夏自然科学基金(NZ10118)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 4156
- HTML全文浏览量: 14
- PDF下载量: 795
- 被引次数: 0
出版历程
- 出版日期: 2011-12-20

Recent advancement of telbivudine in the treatment of chronic hepatitis B

Research funding:

摘要

摘要: 替比夫定是一种新型的抗HBV作用的核苷类似物,其HBeAg血清学转换率高、起效早,耐药发生率低。了解替比夫定的药理作用,选择合适的病例进行治疗,在治疗过程中及时监测,根据第24周时患者的HBV DNA水平来指导后期的治疗,有助于达到长期抑制HBV的目的。
- 肝炎,乙型,慢性 /
- 肝炎病毒,乙型 /
- 替比夫定
Abstract: Telbivudine is a novel nucleoside analogue against hepatitis B virus with fast HBeAg seroconversion rate, early viral response and low drug tolerance rate.It is helpful in achieving the long term suppression of HBV by understanding the pharmacokinetics of Telbivudine, selecting the appropriate patients for treatment, timely monitoring the patients during treatment and guiding post-treatment by the patient's first 24 weeks HBV-DNA levels.
- hepatitis B /
- chronic /
- hepatitis B virus

HTML全文

参考文献(21)

[1]Liaw YF, Gane E, Leung N, et al.2Year GLOBE trial re-sults:telbivudine Is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology, 2009, 136 (2) :486-495.

[2] 张卓然, 倪语星, 尚红.病毒性疾病诊断与治疗[M]∥尚红, 褚云卓.嗜肝DNA病毒科.北京:科学出版社, 2009:122-127.

[3]朱贯臣.乙型肝炎和乙肝病毒研究进展[J].国外医学生理、病理科学与临床分册, 1994, 14 (1) :30-33.

[4]Seeger C, Mason WS.Hepatitis B virus biology[J].Micro-biol Mol Biol Rev, 2000, 64 (1) :51-68.

[5]Scaglioni PP, Melegari M, Wands JR.Biologic properties of hepatitis B viral genomes with mutations in the precore pro-moter and precore open reading frame[J].Virology, 1997, 233 (2) :374-81.

[6]詹万雷, 崔东, 林影, 等.乙肝病毒研究进展[J].广东医学, 2004, 25 (3) :336-337.

[7]Bridges EG, Selden JR, Luo S.Nonclinical Safety Profile of Telbivudine Novel Potent AntiviralAgent for Treatment of Hepatitis B[J].Antimicro Agents Chemother, 2008, 52 (7) :2521-2528.

[8]Milich D, Liang TJ.Exploring the biological basis of hepati-tisB eantigen in hepatitis B virus infection[J].Hepatology, 2003, 38 (5) :1075-1086.

[9]Yim HJ, Lok AS.Natural history of chronic hepatitis B virus infection:what we knew in1981and what we know in2005[J].Hepatology, 2006, 43 (2Suppl1) :S173-S181.

[10]耿书英, 陈金军, 万铁林, 等.核苷类似物治疗HBeAg阳性慢性乙型肝炎完全应答患者的病毒学特点[J].临床肝胆病杂志, 2009, 25 (3) :177-179.

[11]虞作春, 蒋卫民, 尹有宽, 等.核苷类似物治疗慢性乙型肝炎快速应答良好和快速应答不良患者的病毒学应答比较[J].中华传染病杂志, 2008, 26 (2) :103-104.

[12]张夏华, 吴广通, 石玉岚, 等.替比夫定对慢性乙型肝炎HBeAg作用的有关因素探讨[J].中国现代应用药学, 2010, 27 (8) :750-753.

[13]Hou JL, Yin YK, Xu D, et al.A phase III comparative trial of telbivudine and Lamivudine for treatment of chronic hepatitis B in Chinese patients:first year results.Presented at:Shanghai-Hong Kong International Liver Congress, March 25-28, 2006.Poster180.

[14]占国清, 谭华炳, 李儒贵, 等.替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效观察[J].实用肝脏病杂志, 2011, 14 (1) :23-24.

[15]张健珍, 杨葆业, 陈铿, 等.替比夫定与恩替卡韦治、疗HBeAg阳性慢性乙型肝炎的对比研究[J].实用医学杂志, 2010, 26 (14) :2609-2611.

[16]周岳进.替比夫定对拉米夫定和阿德福韦酯耐药的慢性乙型肝炎疗效察[J].肝脏, 2009, 14 (1) :80-81.

[17]Lai CL, Gane E, Liaw YF, et al.Telbivudine versus lamivudi-ne in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) :2576-2588.

[18]杜宁, 胡瑾华, 王慧芬.替比夫定导致周围神经病变3例报道[J].传染病信息, 2009, 22 (4) :245-255.

[19]Yuen MF, Fung J, Seto WK, et al.Combination of baseline pa-rameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy[J].Anti-vir Ther, 2009, 14 (5) :679-685.

[20]Zeuzem S, Gane E, Liaw YF, et al.Baseline characteristics and early on-treatment response predict the outcomes of2 years of telbivudine treatment of chronic hepatitis B[J].J Hepatol, 2009, 51 (1) :11-20.

[21]庄辉, 翁心华.核苷 (酸) 类似物抗病毒治疗慢性乙型肝炎的优化策略[J].临床肝胆病杂志, 2011, 27 (4) :340-342.

施引文献

资源附件(0)

访问统计